# Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

> **NCT04279847** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Incyte Corporation** · enrollment: 140 (actual)

## Conditions studied

- Myelofibrosis
- Myelodysplastic Syndrome
- Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome
- Myeloproliferative Neoplasm
- Relapsed or Refractory Primary Myelofibrosis
- Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)
- ET (Essential Thrombocythemia)

## Interventions

- **DRUG:** INCB057643
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04279847
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-23
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04279847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04279847, "Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04279847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*